Davies JA - Search Results

1

Engineering Adenoviral Vectors with Improved GBM Selectivity.

Bates EA, Lovatt C, Plein AR, Davies JA, Siebzehnrubl FA, Parker AL. Bates EA, et al. Among authors: davies ja. Viruses. 2023 Apr 28;15(5):1086. doi: 10.3390/v15051086. Viruses. 2023. PMID: 37243172 Free PMC article.

2

Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.

Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL. Uusi-Kerttula H, et al. Viruses. 2015 Nov 24;7(11):6009-42. doi: 10.3390/v7112923. Viruses. 2015. PMID: 26610547 Free PMC article. Review.

3

The Fiber Knob Protein of Human Adenovirus Type 49 Mediates Highly Efficient and Promiscuous Infection of Cancer Cell Lines Using a Novel Cell Entry Mechanism.

Baker AT, Davies JA, Bates EA, Moses E, Mundy RM, Marlow G, Cole DK, Bliss CM, Rizkallah PJ, Parker AL. Baker AT, et al. Among authors: davies ja. J Virol. 2021 Jan 28;95(4):e01849-20. doi: 10.1128/JVI.01849-20. Print 2021 Jan 28. J Virol. 2021. PMID: 33268514 Free PMC article.

4

Efficient Intravenous Tumor Targeting Using the αvβ6 Integrin-Selective Precision Virotherapy Ad5_NULL-A20.

Davies JA, Marlow G, Uusi-Kerttula HK, Seaton G, Piggott L, Badder LM, Clarkson RWE, Chester JD, Parker AL. Davies JA, et al. Viruses. 2021 May 8;13(5):864. doi: 10.3390/v13050864. Viruses. 2021. PMID: 34066836 Free PMC article.

5

Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies.

Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, Stanton RJ, Chester JD, Parker AL. Uusi-Kerttula H, et al. Hum Gene Ther. 2015 May;26(5):320-9. doi: 10.1089/hum.2015.015. Hum Gene Ther. 2015. PMID: 25919378 Free PMC article.

6

Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.

Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, Chester JD, Parker AL. Uusi-Kerttula H, et al. Oncotarget. 2016 May 10;7(19):27926-37. doi: 10.18632/oncotarget.8545. Oncotarget. 2016. PMID: 27056886 Free PMC article.

7

Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions.

Baker AT, Greenshields-Watson A, Coughlan L, Davies JA, Uusi-Kerttula H, Cole DK, Rizkallah PJ, Parker AL. Baker AT, et al. Among authors: davies ja. Nat Commun. 2019 Feb 14;10(1):741. doi: 10.1038/s41467-019-08599-y. Nat Commun. 2019. PMID: 30765704 Free PMC article.

8

Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor.

Baker AT, Mundy RM, Davies JA, Rizkallah PJ, Parker AL. Baker AT, et al. Among authors: davies ja. Sci Adv. 2019 Sep 4;5(9):eaax3567. doi: 10.1126/sciadv.aax3567. eCollection 2019 Sep. Sci Adv. 2019. PMID: 31517055 Free PMC article.

9

Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications.

Hulin-Curtis SL, Davies JA, Nestić D, Bates EA, Baker AT, Cunliffe TG, Majhen D, Chester JD, Parker AL. Hulin-Curtis SL, et al. Among authors: davies ja. Cancer Gene Ther. 2020 Nov;27(10-11):785-798. doi: 10.1038/s41417-019-0156-0. Epub 2020 Jan 6. Cancer Gene Ther. 2020. PMID: 31902944 Free PMC article.

10

Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10.

Bates EA, Davies JA, Váňová J, Nestić D, Meniel VS, Koushyar S, Cunliffe TG, Mundy RM, Moses E, Uusi-Kerttula HK, Baker AT, Cole DK, Majhen D, Rizkallah PJ, Phesse T, Chester JD, Parker AL. Bates EA, et al. Among authors: davies ja. Mol Ther Oncolytics. 2022 Mar 16;25:43-56. doi: 10.1016/j.omto.2022.03.007. eCollection 2022 Jun 16. Mol Ther Oncolytics. 2022. PMID: 35399606 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

586 results

Search Page